The biomarker showed independent associations with cognitive and functional decline, offering complementary information alongside p-tau217 in early symptomatic Alzheimer's disease.
Circular Genomics has secured exclusive rights from Washington University and Max Delbrück Center to develop a blood-based Alzheimer’s test using circular RNA biomarkers.
The financing will accelerate clinical validation and commercial readiness of brain-derived blood biomarkers based on circular RNA technology.
The test measures phosphorylated Tau 181 protein to help rule out Alzheimer’s-related amyloid pathology in patients 55 and older.
Read More
The single-plex assay, for research use only, measures brain-derived phosphorylated tau 217 from plasma, serum, and dried blood spots without requiring cerebrospinal fluid collection.
Read More
C2N Diagnostics has expanded the intended use of its PrecivityAD2 Alzheimer’s disease blood test to include patients 50 years and older, lowering the previous age limit from 60 years.
Read More
A Rutgers research director outlines clinical applications and limitations of the new diagnostic tool while highlighting the need for specialist interpretation.
Read More
The test offers a less invasive alternative to cerebrospinal fluid testing and PET scans for detecting amyloid plaques.
Read More
The surface-enhanced Raman spectroscopy platform can detect amyloid beta biomarkers at ultra-low concentrations in body fluids, potentially enabling earlier diagnosis and monitoring of disease progression.
Read More
ALZpath pTau217 antibody data was included in 37 submissions at AAIC, building on research demonstrating its sensitivity and accuracy in blood-based tests for Alzheimer’s disease.
Read More
The Alzheimer’s Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Read More
AI-enhanced EEG technology is emerging as a promising tool for early detection of Alzheimer’s disease, potentially facilitating prevention efforts before symptoms appear.
Read More
At the Alzheimer’s Association International Conference, Roche shared new data on its investigational antibody trontinemab and its Elecsys pTau217 blood test.
Read More
Blood-based biomarker tests are revolutionizing Alzheimer’s diagnostic testing and management of Alzheimer’s disease.
Read More
A Finnish study reveals that Alzheimer’s-related blood biomarkers can be detected in middle age, potentially spotting the disease sooner.
Read More
AI-enhanced EEG technology offers a promising, accessible way to detect early signs of Alzheimer’s disease—years before symptoms appear.
Read More
Quest Diagnostics will offer a Fujirebio blood test this summer to enhance early detection of Alzheimer’s disease.
Read More
Quanterix Corporation’s HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration in South Korea.
Read More